Bayer To Split Off Consumer Or Crop Science, Or Both, Or Neither
After a miserable third quarter the German group is cutting jobs and considering splitting up, but concrete decisions are thin on the ground.
You may also be interested in...
After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.
There may be a trend towards spinning off business units but Merck continues to sees its three-pillar structure as providing the best protection from downturns in any individual segment.
A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.